Prab: CSV import

2024-12-11T02:56:16Z

CSV import

← Older revision		Revision as of 02:56, 11 December 2024
Line 1:		Line 1:
	= Insulin ~~Glargine~~ =		{{Short description\|An article about the long-acting insulin analog, Insulin glargine}}
			{{Infobox drug
			\| name = Insulin glargine
			\| image = [[File:Toujeo 300 IU-ml inj.jpg\|thumb]]
			\| caption = Toujeo, a brand of insulin glargine
			\| tradename = Lantus, Toujeo, Basaglar
			\| class = Long-acting insulin analog
			\| pregnancy_category = C
			\| legal_status = Rx-only
			\| routes_of_administration = Subcutaneous
			\| bioavailability = 60%
			\| onset = 1-2 hours
			\| duration_of_action = 24 hours
			}}

	[[~~File:InsulinHexamer~~.~~jpg\|thumb\|right\|Molecular structure~~ of ~~Insulin Glargine~~]]		'''Insulin glargine''' is a long-acting [[insulin]] analog used in the management of [[diabetes mellitus]]. It is designed to provide a steady level of insulin over a 24-hour period, helping to control blood sugar levels in individuals with [[type 1 diabetes]] and [[type 2 diabetes]].

	Insulin ~~Glargine, commonly known under the brand name Lantus,~~ is a ~~long-acting~~ insulin analog ~~used to control blood sugar levels in patients with diabetes~~. ~~This laboratory-made hormone~~ is ~~designed to provide more consistent blood sugar control compared to regular~~ insulin.		==Pharmacology==
			Insulin glargine is a recombinant human insulin analog. It is produced by modifying the amino acid sequence of human insulin, which alters its solubility and absorption characteristics. Upon subcutaneous injection, insulin glargine forms microprecipitates in the subcutaneous tissue, from which small amounts of insulin are slowly released into the bloodstream.

	~~== Overview ==~~		The onset of action for insulin glargine is typically 1 to 2 hours after injection, with a duration of action lasting up to 24 hours. This provides a basal level of insulin, mimicking the natural basal insulin secretion of the pancreas.
	~~Insulin Glargine is a recombinant form~~ of insulin, ~~used primarily for the management~~ of ~~Type 1 and Type 2 diabetes~~. ~~It helps in regulating the metabolism~~ of ~~carbohydrates~~, ~~fats, and proteins by promoting~~ the ~~absorption~~ of ~~glucose from~~ the ~~blood into liver, fat, and skeletal muscle cells~~.

	~~<youtube>~~		==Clinical Use==
	~~title~~=~~'''{{PAGENAME}}'''~~		Insulin glargine is indicated for the treatment of adults and children with type 1 diabetes and adults with type 2 diabetes who require basal insulin for the control of hyperglycemia. It is usually administered once daily, at the same time each day, to maintain consistent blood glucose levels.
	~~movie_url~~=~~http://www.youtube.com/v/Bq1zsZ3_CPU~~
	~~&rel=~~1
	~~embed_source_url=http://www~~.~~youtube~~.~~com/v/Bq1zsZ3_CPU~~
	~~&rel=1~~
	~~wrap = yes~~
	~~width=750~~
	~~height=600~~
	~~</youtube>~~

	== ~~Chemical Structure and Function~~ ==		===Dosing===
	~~Insulin Glargine differs from human~~ insulin ~~in its amino acid sequence~~, ~~which~~ results ~~in a lower solubility at physiological pH~~. ~~This feature allows for a slower and more predictable absorption rate, ensuring a consistent insulin level for a longer period~~.		The dose of insulin glargine is individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals. It is important to adjust the dose based on regular monitoring of blood glucose levels to avoid [[hypoglycemia]] or [[hyperglycemia]].

	== ~~Clinical Use~~ ==		==Side Effects==
	~~=== Indications ===~~		Common side effects of insulin glargine include hypoglycemia, injection site reactions, and weight gain. Hypoglycemia is the most common adverse effect and can be serious if not managed promptly. Patients should be educated on recognizing the symptoms of hypoglycemia and how to treat it.
	* Management of ~~Type 1 diabetes~~
	* Management of Type 2 diabetes, ~~particularly in cases where blood sugar~~ is not ~~adequately controlled by oral antidiabetic drugs~~

	==~~= Administration =~~==		==Comparison with Other Insulins==
	* Administered via subcutaneous injection		Insulin glargine is one of several long-acting insulin analogs available. It is often compared with [[insulin detemir]] and [[insulin degludec]], which are also used to provide basal insulin coverage. Each of these insulins has unique pharmacokinetic properties that may make one more suitable than another for a particular patient.
	* Typically used ~~once daily, often at bedtime~~

	== ~~Comparisons with Other Insulins~~ ==		==Also see==
	~~Compared to short-acting insulin,~~ Insulin ~~Glargine provides a more stable, peakless, and prolonged insulin release, reducing the risk of nocturnal hypoglycemia.~~		* [[Diabetes mellitus]]
			* [[Insulin therapy]]
			* [[Hypoglycemia]]
			* [[Insulin detemir]]
			* [[Insulin degludec]]

	~~== Side Effects and Precautions ==~~		{{Diabetes drugs}}
	~~While generally well-tolerated,~~ Insulin ~~Glargine may cause side effects such as:~~		{{Insulin analogs}}
	* Hypoglycemia (low blood sugar)
	* Injection site reactions
	* Allergic reactions in rare cases

	~~Patients should monitor blood sugar levels regularly and adjust the dose under medical supervision.~~		[[Category:Insulin therapies]]
			[[Category:Diabetes management]]
	~~== Pharmacological Classification ==~~
	~~Insulin Glargine is classified as a long-acting insulin analog and falls under the category of therapeutic insulin.~~

	~~== Development and Approval ==~~
	~~Developed by Sanofi-Aventis, Insulin Glargine was first approved for medical use in the United States in 2000. Since then, it has become a widely used insulin analog worldwide.~~

	~~== References ==~~
	~~<references>~~
	* [~~https~~:~~//www.drugs.com/monograph/insulin-glargine.html "~~Insulin ~~Glargine Monograph for Professionals"~~] ~~- Drugs.com~~
	* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1473036/ "Insulin Glargine: A Review of its Therapeutic Use as a Long-acting Agent for the Management of Type 1 and 2 Diabetes Mellitus"] ~~- NCBI~~
	~~</references>~~

	[[Category:Diabetes]]
	~~[[Category:Pharmacology]]~~
	~~[[Category:Endocrinology]]~~

	~~{{stub}}~~

Kondreddy Naveen at 15:19, 22 December 2023

2023-12-22T15:19:02Z

New page

= Insulin Glargine =

[[File:InsulinHexamer.jpg|thumb|right|Molecular structure of Insulin Glargine]]

Insulin Glargine, commonly known under the brand name Lantus, is a long-acting insulin analog used to control blood sugar levels in patients with diabetes. This laboratory-made hormone is designed to provide more consistent blood sugar control compared to regular insulin.

== Overview ==
Insulin Glargine is a recombinant form of insulin, used primarily for the management of Type 1 and Type 2 diabetes. It helps in regulating the metabolism of carbohydrates, fats, and proteins by promoting the absorption of glucose from the blood into liver, fat, and skeletal muscle cells.

<youtube>
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v/Bq1zsZ3_CPU
&rel=1
embed_source_url=http://www.youtube.com/v/Bq1zsZ3_CPU
&rel=1
wrap = yes
width=750
height=600
</youtube>

== Chemical Structure and Function ==
Insulin Glargine differs from human insulin in its amino acid sequence, which results in a lower solubility at physiological pH. This feature allows for a slower and more predictable absorption rate, ensuring a consistent insulin level for a longer period.

== Clinical Use ==
=== Indications ===
* Management of Type 1 diabetes
* Management of Type 2 diabetes, particularly in cases where blood sugar is not adequately controlled by oral antidiabetic drugs

=== Administration ===
* Administered via subcutaneous injection
* Typically used once daily, often at bedtime

== Comparisons with Other Insulins ==
Compared to short-acting insulin, Insulin Glargine provides a more stable, peakless, and prolonged insulin release, reducing the risk of nocturnal hypoglycemia.

== Side Effects and Precautions ==
While generally well-tolerated, Insulin Glargine may cause side effects such as:
* Hypoglycemia (low blood sugar)
* Injection site reactions
* Allergic reactions in rare cases

Patients should monitor blood sugar levels regularly and adjust the dose under medical supervision.

== Pharmacological Classification ==
Insulin Glargine is classified as a long-acting insulin analog and falls under the category of therapeutic insulin.

== Development and Approval ==
Developed by Sanofi-Aventis, Insulin Glargine was first approved for medical use in the United States in 2000. Since then, it has become a widely used insulin analog worldwide.

== References ==
<references>
* [https://www.drugs.com/monograph/insulin-glargine.html "Insulin Glargine Monograph for Professionals"] - Drugs.com
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1473036/ "Insulin Glargine: A Review of its Therapeutic Use as a Long-acting Agent for the Management of Type 1 and 2 Diabetes Mellitus"] - NCBI
</references>

[[Category:Diabetes]]
[[Category:Pharmacology]]
[[Category:Endocrinology]]

{{stub}}

Insulin glargine - Revision history

Prab: CSV import

Kondreddy Naveen at 15:19, 22 December 2023